Canary Speech Appoints Dr. Kang Hsu as Chief Medical Officer to Lead Clinical Strategy and Expand Voice Biomarker Adoption.
PorAinvest
martes, 12 de agosto de 2025, 1:16 pm ET1 min de lectura
MSFT--
In his new role, Dr. Hsu will work closely with strategic partners such as Mayo Clinic, Microsoft, Samsung, LG NOVA, and major health systems. He will contribute to Canary Speech's research efforts, collaborating with academic and industry partners to help advance the scientific development and clinical validation of voice biomarkers. Additionally, Dr. Hsu will serve as a public-facing voice for Canary Speech, helping build awareness and thought leadership in this rapidly evolving field.
"We are thrilled to welcome Dr. Hsu to the team," said Henry O'Connell, CEO of Canary Speech. "His background in informatics, health system strategy, and patient-centered care brings an extraordinary depth of experience to Canary Speech. As we scale our ambient voice platform, Dr. Hsu's insight will be invaluable in shaping our clinical models, validating new use cases, and forging strategic partnerships."
Dr. Hsu most recently served as Associate Vice President for Acute Medical Informatics at Providence, where he helped integrate clinical informatics, pharmacy, genomics, research, and lab initiatives across a broad care continuum. A board-certified internist and clinical informaticist, he has held senior leadership roles at Providence, St. Joseph Health, and MEDITECH.
This appointment reflects Canary Speech's ongoing commitment to transforming healthcare through real-time, voice-enabled tools that support early detection, remote care, and proactive intervention.
References:
[1] https://www.prnewswire.com/news-releases/canary-speech-appoints-dr-kang-hsu-jr-as-chief-medical-officer-to-lead-clinical-strategy-and-expand-voice-biomarker-adoption-302528044.html
[2] https://finance.yahoo.com/news/canary-speech-appoints-dr-kang-171100541.html
NVMI--
Canary Speech has appointed Dr. Kang Hsu, Jr. as its new Chief Medical Officer to lead the company's clinical strategy and expand its voice biomarker adoption. Dr. Hsu has over two decades of clinical, operational, and digital health experience and will oversee Canary Speech's clinical direction, support product development, and collaborate with strategic partners to advance the scientific development and clinical validation of voice biomarkers. He will also contribute to the company's research efforts and help build awareness and thought leadership in this rapidly evolving field.
Canary Speech, a leading AI-powered voice biomarker health tech company, has appointed Dr. Kang Hsu, Jr. as its new Chief Medical Officer (CMO). Dr. Hsu, who brings over two decades of clinical, operational, and digital health experience, will oversee the company's clinical direction and support product development. He will also collaborate with strategic partners to advance the scientific development and clinical validation of voice biomarkers.In his new role, Dr. Hsu will work closely with strategic partners such as Mayo Clinic, Microsoft, Samsung, LG NOVA, and major health systems. He will contribute to Canary Speech's research efforts, collaborating with academic and industry partners to help advance the scientific development and clinical validation of voice biomarkers. Additionally, Dr. Hsu will serve as a public-facing voice for Canary Speech, helping build awareness and thought leadership in this rapidly evolving field.
"We are thrilled to welcome Dr. Hsu to the team," said Henry O'Connell, CEO of Canary Speech. "His background in informatics, health system strategy, and patient-centered care brings an extraordinary depth of experience to Canary Speech. As we scale our ambient voice platform, Dr. Hsu's insight will be invaluable in shaping our clinical models, validating new use cases, and forging strategic partnerships."
Dr. Hsu most recently served as Associate Vice President for Acute Medical Informatics at Providence, where he helped integrate clinical informatics, pharmacy, genomics, research, and lab initiatives across a broad care continuum. A board-certified internist and clinical informaticist, he has held senior leadership roles at Providence, St. Joseph Health, and MEDITECH.
This appointment reflects Canary Speech's ongoing commitment to transforming healthcare through real-time, voice-enabled tools that support early detection, remote care, and proactive intervention.
References:
[1] https://www.prnewswire.com/news-releases/canary-speech-appoints-dr-kang-hsu-jr-as-chief-medical-officer-to-lead-clinical-strategy-and-expand-voice-biomarker-adoption-302528044.html
[2] https://finance.yahoo.com/news/canary-speech-appoints-dr-kang-171100541.html

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema



Comentarios
Aún no hay comentarios